Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/161425
Kind Code:
A1
Abstract:
Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumors.

Inventors:
ZHAO XIAOFENG (CN)
LU SHIQIANG (CN)
CAO ZHUOXIAO (CN)
TANG RENHONG (CN)
REN JINSHENG (CN)
Application Number:
PCT/CN2022/074228
Publication Date:
August 04, 2022
Filing Date:
January 27, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
JIANGSU SIMCERE PHARM CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; A61P35/04; C12N15/13
Domestic Patent References:
WO2020089474A12020-05-07
Foreign References:
CN109476745A2019-03-15
Attorney, Agent or Firm:
UNITALEN ATTORNEYS AT LAW (CN)
Download PDF:



 
Previous Patent: SAMPLING DEVICE

Next Patent: ELECTRIC VALVE